PYC Therapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

PYC TherapeuticsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -32.3% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 52.4% pro Jahr.

Wichtige Informationen

-32.3%

Wachstumsrate der Gewinne

-26.1%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	9.6%
Wachstumsrate der Einnahmen	52.4%
Eigenkapitalrendite	-47.0%
Netto-Marge	-171.0%
Letzte Ertragsaktualisierung	30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Keine Aktualisierungen

Recent updates

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Feb 20

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

Jan 26

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

Dec 22

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

Nov 17

Aufschlüsselung der Einnahmen und Ausgaben

Wie PYC Therapeutics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

ASX:PYC Einnahmen, Ausgaben und Erträge (AUD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 24	22	-38	5	56
31 Mar 24	22	-30	4	48
31 Dec 23	21	-22	4	39
30 Sep 23	19	-22	4	37
30 Jun 23	16	-23	4	35
31 Mar 23	15	-23	5	34
31 Dec 22	14	-24	6	33
30 Sep 22	15	-19	6	28
30 Jun 22	16	-14	6	24
31 Mar 22	13	-15	7	21
31 Dec 21	9	-17	8	18
30 Sep 21	6	-17	8	16
30 Jun 21	3	-18	8	14
31 Mar 21	3	-15	6	12
31 Dec 20	2	-12	4	11
30 Sep 20	2	-9	4	8
30 Jun 20	2	-7	4	6
31 Mar 20	1	-6	4	3
31 Dec 19	0	-5	4	0
30 Sep 19	0	-5	3	0
30 Jun 19	0	-4	2	0
31 Mar 19	0	-4	1	0
31 Dec 18	0	-5	1	0
30 Sep 18	0	-6	2	0
30 Jun 18	0	-7	3	0
31 Mar 18	0	-6	3	0
31 Dec 17	0	-5	4	0
30 Sep 17	1	-3	3	0
30 Jun 17	3	-2	2	0
31 Mar 17	3	-3	2	0
31 Dec 16	3	-4	2	0
30 Sep 16	1	-4	1	0
30 Jun 16	0	-4	1	0
31 Mar 16	0	-4	2	0
31 Dec 15	0	-4	2	0
30 Sep 15	0	-3	2	0
30 Jun 15	1	-3	2	0
31 Mar 15	1	-3	2	0
31 Dec 14	1	-3	2	0
30 Sep 14	1	-3	2	0
30 Jun 14	1	-3	2	0
31 Mar 14	1	-3	2	0
31 Dec 13	1	-3	2	0

Qualität der Erträge: PYC ist derzeit unrentabel.

Wachsende Gewinnspanne: PYC ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: PYC ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 32.3% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von PYC verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: PYC ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (2.7%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: PYC hat eine negative Eigenkapitalrendite (-47.02%), da es derzeit unrentabel ist.

PYC Therapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

New minor risk - Market cap size

We're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely

Price target increased by 8.2% to AU$0.33

PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024

Price target increased by 9.1% to AU$0.30

Insufficient new directors

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Price target decreased by 15% to AU$0.29

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

New minor risk - Financial data availability

PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program

New minor risk - Share price stability

We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration

Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

High number of new and inexperienced directors

PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials

PYC Therapeutics Limited, Annual General Meeting, Nov 23, 2022

PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline

Non-Executive Chair of the Board recently bought AU$103k worth of stock

PYC Therapeutics Limited Announces Exemplary PK Study Results Move RP11 Program Closer to First in Human Trials

High number of new and inexperienced directors

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited Enters into the Next Phase of Preclinical Development for VP-001

PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy

CEO & Director exercised options to buy AU$1.6m worth of stock.

PYC Therapeutics to Develop A New Generation of RNA Therapeutics

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease ­ Autosomal Dominant Optic Atrophy

We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - a First for Any Rp11 Treatment to-Date

PYC Therapeutics Names Glenn Noronha as Chief Development Officer

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Non-Executive Chair of the Board recently bought AU$81k worth of stock

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

PYC Therapeutics Limited Announces Visual Evidence of Lead Drugs Efficacy

PYC Therapeutics Limited Appoints Sahm Nasseri as CEO of Us Operations and as Director of the Board

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

PYC Therapeutics Announces to Developing New Treatments for Severe Unmet Patient Needs

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

PYC Therapeutics Limited Develops New Treatments for Severe Unmet Patient Needs

PYC Therapeutics Limited Files for Intellectual Property Protection for the New Drug Candidate

PYC Therapeutics Limited Announces CEO Changes

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease Autosomal Dominant Optic Atrophy